63.56
2.75%
-1.7774
Cytokinetics Inc stock is currently priced at $63.56, with a 24-hour trading volume of 317.86K.
It has seen a -2.75% decreased in the last 24 hours and a -9.37% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $65.32 pivot point. If it approaches the $62.90 support level, significant changes may occur.
Previous Close:
$65.34
Open:
$64.95
24h Volume:
317.86K
Market Cap:
$6.64B
Revenue:
$7.53M
Net Income/Loss:
$-526.24M
P/E Ratio:
-11.51
EPS:
-5.52
Net Cash Flow:
$-415.75M
1W Performance:
-4.15%
1M Performance:
-9.37%
6M Performance:
+100.19%
1Y Performance:
+69.89%
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
650-624-3000
Address
280 East Grand Avenue, South San Francisco, CA
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-24-24 | Downgrade | UBS | Buy → Neutral |
Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-09-23 | Initiated | Goldman | Buy |
Nov-07-23 | Initiated | B. Riley Securities | Buy |
Aug-15-23 | Initiated | SVB Securities | Outperform |
Feb-17-23 | Initiated | BofA Securities | Neutral |
Dec-23-22 | Reiterated | Needham | Buy |
Dec-20-22 | Initiated | Truist | Buy |
Oct-11-22 | Initiated | UBS | Buy |
Jan-28-22 | Initiated | Goldman | Buy |
Dec-22-21 | Initiated | Oppenheimer | Outperform |
Dec-10-21 | Initiated | JP Morgan | Overweight |
Oct-07-21 | Initiated | Jefferies | Buy |
Mar-12-21 | Initiated | Wolfe Research | Outperform |
Feb-18-21 | Initiated | Barclays | Overweight |
Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
Oct-29-20 | Initiated | Goldman | Neutral |
Jul-10-20 | Initiated | Raymond James | Strong Buy |
May-05-20 | Initiated | Mizuho | Buy |
Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
Jul-31-17 | Initiated | Morgan Stanley | Overweight |
Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
Jul-28-16 | Reiterated | Needham | Buy |
Nov-10-15 | Reiterated | FBR Capital | Outperform |
Nov-09-15 | Reiterated | ROTH Capital | Buy |
Jul-24-15 | Reiterated | MLV & Co | Buy |
Dec-31-14 | Reiterated | ROTH Capital | Buy |
Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics to Announce First Quarter Results on May 8, 2024
GlobeNewswire Inc.
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
GlobeNewswire Inc.
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
GlobeNewswire Inc.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
GlobeNewswire Inc.
Cytokinetics Inc Stock (CYTK) Financials Data
Cytokinetics Inc (CYTK) Revenue 2024
CYTK reported a revenue (TTM) of $7.53 million for the quarter ending December 31, 2023, a -92.04% decline year-over-year.
Cytokinetics Inc (CYTK) Net Income 2024
CYTK net income (TTM) was -$526.24 million for the quarter ending December 31, 2023, a -35.30% decrease year-over-year.
Cytokinetics Inc (CYTK) Cash Flow 2024
CYTK recorded a free cash flow (TTM) of -$415.75 million for the quarter ending December 31, 2023, a -33.75% decrease year-over-year.
Cytokinetics Inc (CYTK) Earnings per Share 2024
CYTK earnings per share (TTM) was -$5.45 for the quarter ending December 31, 2023, a -28.24% decline year-over-year.
Cytokinetics Inc Stock (CYTK) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Malik Fady Ibraham | EVP Research & Development |
Apr 09 '24 |
Option Exercise |
6.67 |
28,605 |
190,795 |
171,172 |
Malik Fady Ibraham | EVP Research & Development |
Apr 09 '24 |
Sale |
74.31 |
32,605 |
2,422,918 |
138,567 |
Malik Fady Ibraham | EVP Research & Development |
Mar 05 '24 |
Option Exercise |
6.67 |
28,604 |
190,789 |
167,577 |
Malik Fady Ibraham | EVP Research & Development |
Mar 05 '24 |
Sale |
67.56 |
32,604 |
2,202,606 |
138,973 |
HENDERSON JOHN T | Director |
Feb 14 '24 |
Option Exercise |
4.44 |
5,000 |
22,200 |
47,632 |
HENDERSON JOHN T | Director |
Feb 14 '24 |
Sale |
76.48 |
5,000 |
382,400 |
42,632 |
Blum Robert I | President & CEO |
Feb 13 '24 |
Option Exercise |
6.67 |
12,500 |
83,375 |
454,297 |
Blum Robert I | President & CEO |
Feb 13 '24 |
Sale |
76.85 |
12,500 |
960,625 |
441,797 |
Malik Fady Ibraham | EVP Research & Development |
Feb 06 '24 |
Option Exercise |
6.67 |
28,605 |
190,795 |
175,578 |
Malik Fady Ibraham | EVP Research & Development |
Feb 06 '24 |
Sale |
79.30 |
32,605 |
2,585,496 |
142,973 |
About Cytokinetics Inc
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):